CB Biotechnology to acquire Theratechnologies for up to $254m.

CB Biotechnology, an affiliate of pharmaceutical contract manufacturer Future Pak, agreed to acquire Theratechnologies, a Canadian biopharmaceutical company specializing in HIV and oncology treatments, for up to $254m. “This transaction is the result of a thorough and deliberate sale process aimed at maximizing value for our shareholders. Future Pak’s interest in acquiring Theratechnologies represents a vote of confidence in the company we’ve built, recognizing our achievements in bringing innovative medicines to patients and the outstanding contributions of our dedicated employees,” Frank A. Holler, Theratechnologies Chair of the Board of Directors.